您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
Mark Lawrence Chiu
Mark Lawrence Chiu
所属职位: CSO
所属公司:

拓创生物科技(苏州)有限公司

Tavotek Biotherapeutics

Mark Chiu博士深耕医药研发行业超25年,在跨国药企研发管理方面有着丰富的经验。在创办拓创生物前,他曾任美国强生和雅培多个关键研发部门领导,负责多个突破性药物产品的早期研发,如:Darzalex(Daratumumab)、Tremfya (Gesulkumab)、Remicade (Infliximab), Rybruvent (amivantamab), Teclistamab, Ciltacabtagene autoleucel等。仅3年时间,他就为强生研发出9个新分子实体 (NME)。他毕业于加州大学伯克利分校生物物理学士学位和伊利诺伊大学香槟分校生物化学博士学位。博士后期间,曾与两位诺贝尔奖获得者合作,也曾在欧洲和美国科学委员会研究部门工作。 

Dr. Mark Chiu has been in the pharmaceutical development industry for over 25 years and has rich experience in the R&D management of multinational pharmaceutical enterprises. He was the supervisor of multiple key R&D departments in Johnson & Johnson and Abbott, responsible for leading the early R&D of several blockbusting pharmaceutical products, for example Darzalex(Daratumumab)、Tremfya (Gesulkumab)、Remicade (Infliximab), Rybruvent (amivantamab), Teclistamab, Ciltacabtagene autoleucel, etc. before the founding of Tavotek Pharmaceuticals. Within only three years, he developed nine new molecular entities (NME) for Johnson & Johnson. He graduated with a BA Biophysics from the University of California Berkeley and Ph.D Biochemistry from the University of Illinois Urbana-Champaign.   He was a post-doctoral fellow working with two Nobel winners, was in study sections in European and United States Scientific Committees. 


微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务